Formoterol vs short‐acting beta2‐agonist
Patients with a serious adverse event (all cause) · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
- Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes onlyOR 0.94 [0.81, 1.08]7 studies · 22538 participantsLow